Reduced thrombospondin-1 immunostaining is significantly associated with increased recurrence, decreased survival and the expression of mutant p53 [119], and the in vitro secretion of thrombospondin-1 by bladder cancer cells is significantly lower than that secreted by normal urothelial cells [123]. The gene discussed is TP53; the disease is urinary bladder carcinoma.